Mutations in MRTs consist of inactivating deletions or truncations of SMARCB1 [53], and loss of SMARCB1 leads to a global decrease in its occupancy at enhancer and promoter regions [71] as opposed to the relocalization seen in synovial sarcoma. This evidence concerns the gene SMARCB1 and synovial sarcoma.